---
title: "WuXi AppTec Co., Ltd. Class H (2359) Receives a Buy from Goldman Sachs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284635291.md"
description: "Goldman Sachs analyst Ziyi Chen has assigned a Buy rating to WuXi AppTec Co., Ltd. Class H (2359) with a price target of HK$169.40. The stock closed at HK$143.10. Chen, who focuses on the Healthcare sector, has an average return of 2.8% and a 45.68% success rate on recommendations. The analyst consensus for WuXi AppTec is Strong Buy, with a price target consensus of HK$157.63."
datetime: "2026-04-29T20:05:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284635291.md)
  - [en](https://longbridge.com/en/news/284635291.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284635291.md)
---

# WuXi AppTec Co., Ltd. Class H (2359) Receives a Buy from Goldman Sachs

Goldman Sachs analyst Ziyi Chen assigned a Buy rating to WuXi AppTec Co., Ltd. Class H yesterday and set a price target of HK$169.40. The company’s shares closed today at HK$143.10.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Chen covers the Healthcare sector, focusing on stocks such as Livzon Pharmaceutical Group, 3SBio, and Legend Biotech. According to TipRanks, Chen has an average return of 2.8% and a 45.68% success rate on recommended stocks.

WuXi AppTec Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of HK$157.63.

### Related Stocks

- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [688336.CN](https://longbridge.com/en/quote/688336.CN.md)

## Related News & Research

- [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md)
- [07:55 ETSupport Egg Quality and Ovulation with Nature's Bounty® New Fertility Supplement*](https://longbridge.com/en/news/285200796.md)
- [Hengrui Pharma Sets Formal Remuneration and Evaluation Committee to Bolster Governance](https://longbridge.com/en/news/284607220.md)
- [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md)
- [05:22 ETEnergenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026](https://longbridge.com/en/news/284533464.md)